skip to content

FDA approves Roche’s RozlytrekTM (entrectinib) for people with ROS1-positive, metastatic non-small cell lung cancer and NTRK gene fusion-positive solid tumours

Media

Media releases
view all

stay updated

get the latest news and updates to your inbox.